Searched for
IMMUNOACT
Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...- IIT Bombay's small investment of Rs 4,080 in Sedemac turns to Rs 55 crore in IPOIIT Bombay’s incubator SINE is set to turn a Rs 4,080 investment in Sedemac Mechatronics into Rs 55 crore as the company’s IPO nears closur...
- Ravindranath Kancherla on why most healthcare innovation never reaches patients and how India can change thatDr. Ravindranath Kancherla, the founder of Global Hospitals and Global HealthX reflects on how India can emerge as a global proving ground ...
- Campus incubators hoping for the next million-dollar startupTaking cue from IIT Madras, several colleges are deepening their footprints across India’s burgeoning startup ecosystem, upgrading their in...
- Homegrown cell, gene therapy pioneer ImmunoACT turns profitable in first year of opsImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ...
- Gene therapy for blood cancer shows 73 per cent response rate in clinical trialsResearchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-inco...
- China’s biotech is redrawing the global pharma map; what India can learnAmerican biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. Astr...
- Ajay Hinduja on advancing cancer care: Insights on CAR-T therapy innovationIndia has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja Hospital, led by Dr. ...
- CDSCO approves India's first CAR-T cell therapy against certain blood cancersIndian company ImmunoACT, backed by drug maker Laurus Labs, has received approval from the Central Drugs Standard Control Organization for ...
- Laurus Labs shares rise over 4% as co acquires additional stake in lmmunoACTLaurus Labs is set to increase its stake in Immunoadoptive Cell Therapy (lmmunoACT) by 7.24% for $10.6m, taking its total stake in the comp...
- Stocks in news: South Indian Bank, Coal India, HDFC Life, SAIL, Adani GreenSouth Indian Bank has finalised the candidates for the post of MD and CEO of the Bank. The lender will submit the application to the RBI se...
- Laurus Labs invests Rs 80 crore in cell & gene therapy firm ImmunoACTThe fresh infusion of capital will enable ImmunoACT to fast-track the scale-up of its lead candidate HCAR-19 by expansion of the multi-loca...
- Seeking technology, manufacturing partnership with Indian pharma companies, says Mexico foreign secretaryThe Mexican government has partnered with ImmunoAct, an IIT Bombay-incubated company which is developing cutting-edge chimeric antigen rece...
- How Laurus Labs capex drive can impact its margins & valuationsRise in headwinds in the pharma industry due to inflation, increase in raw material costs, and excessive competition led to price erosion i...
- The week that was: Latent View logs 250% return in a week, Paytm makes a recoveryThe volatility was high with India VIX surging to 20.80 level from 14.85 level a week ago amid the expiry of the monthly F&O series. That s...
- Stocks in the news: Paytm, Reliance Industries, Bharti Airtel, Sun Pharma and Laurus LabsZydus Cadila said it has received approval from the US health regulator to market Decitabine injection, used to treat certain types of canc...
- Laurus Labs to buy 26% in CAR T-cell therapy companyFounded in 2018 by Dr Rahul Purwar and a team of scientists, ImmunoACT is collaborating with institutions like Tata Memorial Hospital. Carl...
- Laurus Labs acquires stake in IIT-Bombay incubated CAR-T cell therapy companyAs per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subjec...
Load More
